Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

146
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
146
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

341
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
341
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

326
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
326
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

315
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
315
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.1K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

357
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
357

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.

The British journal of dermatology·2026
Same author

Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Journal of asthma and allergy·2026
Same author

Atopic dermatitis Yardstick: A new era of topical and systemic treatments.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Pediatric dermatology·2026
Same author

Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Dec 6, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.5K

Biologics for Atopic Dermatitis.

Mark Boguniewicz1

  • 1Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J310, Denver, CO 80206, USA.

Immunology and Allergy Clinics of North America
|October 5, 2020
PubMed
Summary
This summary is machine-generated.

Atopic dermatitis (AD) is a chronic skin disease with immune and barrier issues. Biologic treatments like dupilumab offer new options for moderate to severe AD.

Keywords:
Atopic dermatitisBiologicsDupilumabImmune dysregulationLebrikizumabNemolizumabOmalizumabTralokinumab

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation
02:36

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation

Published on: March 8, 2024

1.4K

Related Experiment Videos

Last Updated: Dec 6, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.5K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation
02:36

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation

Published on: March 8, 2024

1.4K

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Atopic dermatitis (AD) is a prevalent global skin condition.
  • Pathophysiology involves skin barrier and immune system abnormalities.
  • Type 2 immune deviation is key in AD phenotypes and endotypes.

Purpose of the Study:

  • To review the role of biologics in treating atopic dermatitis.
  • To highlight dupilumab's approval and potential for precision medicine.

Main Methods:

  • Review of current literature on atopic dermatitis pathophysiology.
  • Analysis of biologic treatment options, including dupilumab.
  • Discussion of ongoing clinical trials for monoclonal antibodies.

Main Results:

  • Dupilumab is approved for moderate-to-severe atopic dermatitis in patients 6 years and older.
  • Monoclonal antibodies are advancing through Phase 3 trials.

Conclusions:

  • The systemic nature of AD supports biologic therapies.
  • Biologics and precision medicine represent a promising future for AD treatment.